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Abstract
Gastric cancer (GC) is a major cause of global cancer mortality. Genetic variations in DNA repair
genes can modulate DNA repair capability and, consequently, have been associated with risk of
developing cancer. We have previously identified a T to C point mutation at nucleotide 889
(T889C) in DNA polymerase beta (POLB) gene, a key enzyme involved in base excision repair in
primary GCs. The purpose of this study was to evaluate the mutation and expression of POLB in a
larger cohort and to identify possible prognostic roles of the POLB alterations in GC. Primary GC
specimens and their matched normal adjacent tissues were collected at the time of surgery. DNA,
RNA and protein samples were isolated from GC specimens and cell lines. Mutations were detected by PCR-RFLP/DHPLC and sequencing analysis. POLB gene expression was examined by
RT-PCR, tissue microarray, Western blotting and immunofluorescence assays. The function of the
mutation was evaluated by chemosensitivity, MTT, Transwell matrigel invasion and host cell reactivation assays. The T889C mutation was detected in 18 (10.17%) of 177 GC patients. And the
T889C mutation was associated with POLB overexpression, lymph nodes metastases and poor
tumor differentiation. In addition, patients with- the mutation had significantly shorter survival time
than those without-, following postoperative chemotherapy. Furthermore, cell lines with T889C
mutation in POLB gene were more resistant to the treatment of 5-fluorouracil, cisplatin and epirubicin than those with wild type POLB. Forced expression of POLB gene with T889C mutation
resulted in enhanced cell proliferation, invasion and resistance to anticancer drugs, along with
increased DNA repair capability. These results suggest that POLB gene with T889C mutation in
surgically resected primary gastric tissues may be clinically useful for predicting responsiveness to
chemotherapy in patients with GC. The POLB gene alteration may serve as a prognostic biomarker
for GC.
Key words: DNA polymerase beta (POLB); gastric cancer; DNA Repair; point mutation; chemotherapy.

Introduction
Gastric cancer (GC) is the second leading cause
of cancer-related deaths worldwide [1]. It remains
difficult to cure, primarily due to lack of reliable
screening markers and advanced disease when diagnosed. Even patients who present the most favorable
condition at diagnosis and subsequently undergo
curative surgical resection often die of recurrent dis-

ease [2]. Genetic variations in DNA repair genes can
modulate DNA repair capability and, consequently,
have been associated with the risk of developing
cancer [3]. DNA polymerase beta (POLB) is a DNA repair polymerase involved in base-excision repair
(BER), and recombination and drug resistance [4-6].
Thirty percent of all tumors reported to date harbor
http://www.ijbs.com
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mutations in the POLB gene [7]. Aberrant POLB expression resulted in an increased rate of spontaneous
mutagenesis and a highly mutagenic tolerance phenotype [8, 9]. POLB gene mutation and overexpression have been reported in various cancers [10-14]. In
our previous studies, we identified a novel homozygous T to C point mutation at nucleotide 889 (T889C)
in POLB gene (GenBank Acc# M13140.1) from human
primary GC. This mutation resulted in a substitution
of the amino acid at 259 from Leucine to Serine in
protein [15]. In the present work, we examined the
T889C mutation and expression of POLB in a large
cohort of GC patients with integral follow-up records,
and analyzed the relationship between aberrant POLB
expression and patients’ clinicopathological features.

Materials and Methods
Cell lines and tissue samples
Eight human GC cell lines AGS, N-87, SUN1,
SUN5, SNU16, RF1, RF48 and MKN45 were obtained
from the American Type Culture Collection (ATCC).
Cell lines BGC823, MGC803, SGC7901, PAMC82, and
GES were established in China. Primary GC specimens and their matched normal adjacent tissues were
collected and snap-frozen at the time of surgery. None
of the patients had received any chemotherapy or
radiotherapy before surgical resection. Clinical and
histological features were obtained and evaluated
(Table 1). Fifty peripheral blood samples were obtained from healthy volunteers. The study was conducted according to the Helsinki Declaration, approved by the Institutional Ethical Standards Committee of Peking University. Informed consent of all
study subjects were obtained before the samples were
collected.

DNA isolation and PCR amplification
Genomic DNA was extracted from GC cell lines,
primary GC tissues and their matched normal gastric
tissues, and peripheral blood samples of healthy
volunteers. Since T889C mutation results in a new
Taq1 site from 888 to 891 (TTGA to TCGA) in POLB
gene, which allows us to screen for the point mutation
by Taq1 enzyme digestion (Figure 1A). Specifically,
we used a PCR strategy that can distinguish the
T889C mutation from the wild-type in POLB allele.
The
primers
used
were:
POLB Forward:
5′-CCACTTAGGCTTATCTTTGGT-3′ and Reverse:
5′-GGA CAC TCA CCA GTG ACT CC-3′.

Purification of PCR products and PCR-RFLP
analysis
The PCR products of the expected sizes were
purified with Geneclean Kit (Bio 101, Inc., La Jolla,
Calif.). Ten μl of PCR products were digested with the
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restriction enzyme, TaqI (New England BioLabs, Beverly, Mass.).

PCR-DHPLC and DNA sequencing analysis
DHPLC (denaturing high-performance liquid
chromatography) analysis was performed as described [16, 17]. PCR products showing aberrant
PCR-RFLP banding patterns and exhibiting abnormal
elution peak in DHPLC were subjected to sequencing
analysis.

RT-PCR assays
Five μg of total RNA from each sample was used
for cDNA synthesis, using the MMLV and random
primers (Oligo dT). Two μg of reverse-transcription
product was used as templates to amplify specific
fragment of POLB gene. The expression of housekeeping gene glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was used as an internal control.
The average relative densities of bands were detected
by Bandlead 3.0 program. The expression level was
shown by the ratio of POLB to GAPDH in band density.
Table 1. Clinical and pathological parameters of the 177 patient
samples used in mutation analysis
Tissues parameters
Tumor
Gender
Male
Female
Age (years)
Male
Female
Pathology
Intestinal
Diffuse
Mixed
Adenosquamous
Tumour location
GOJ *
Fundus
Greater curve-body
Lesser curve-body
Body non-specified
Antrum
Differentiation
Well
Moderate to poor
Poor
Depth of invasion
Mucosa
Submucosa
Muscularis propria
Serosa/full thickness
No. of involved Lymph nodes
0
1
1-6
7-15
>15
*

Number
177
125
52
28-86
29-79
116
30
20
11
51
12
18
11
20
65
21
60
96
11
10
31
125
60
5
19
30
63

Gastro-esophageal junction
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Tissue microarray construction and immunohistochemical (IHC) staining and evaluation
Tissue microarrays were constructed as described previously [18]. An affinity purified goat polyclonal antibody POLB (sc-5927, Santa Cruz) was
used for IHC staining. For evaluation, the total fields
were counted microscopically under high power
(×200). The results of POLB expression were graded
as: negative (-), <5% of cell stained; positive (+), >5%
of cells stained.

Western blot analysis
Protein extraction and Western blot analysis
with chemiluminescent detection were as described
[19]. The following antibodies and dilution factors
were used: affinity purified goat polyclonal antibody
POLB (sc-5927, Santa Cruz, 1:800), rabbit anti-actin
(H-196, Santa Cruz, 1:1000), donkey anti-goat
IgG-HRP (sc-2020, Santa Cruz, 1:2000) and goat anti-rabbit IgG-HRP (sc-2030, Santa Cruz, 1:2000).

Association analysis between alterations of
POLB gene and patients’ clinicopathological
features, and their responses to chemotherapy
The association between the point mutation and
clinicopathological features such as gender, age,
pathological diagnosis, differentiation, tumor location, depth of invasion, liver metastasis, and lymph
metastases was analyzed by the paired chi-square test
with SPSS 13.0. p < 0.05 was considered statistically
significant.
To analyze the correlation between T889C mutation and patients’ response to postoperative adjuvant
chemotherapy, we compared progression-free time
and overall survival time of the patients who received
identical anticancer drug treatment, at the same
pathological stage when initially diagnosed.
Regarding surgical operations, patients included
for this study must have received complete surgical
removal of the tumor, with negative pathologic margin, and with the caveat of the anatomical location of
the tumor and the condition of the patients. The degree of surgical resection was assessed by a central
review of operative reports, and pre- and
post-operative imaging. When the results of scans and
operative reports differed, the degree of surgical resection was assessed based on the results of computed
tomography (CT) or magnetic resonance imaging
(MRI). Patients with one of the following two conditions were excluded: 1. underwent unsuccessful surgical procedures (for instance, anastomotic leakage,
fistula, abscess, hemorrhage); 2. had “medical” complications caused by non-malignant diseases or uncontrolled infections, which were detected by the following examinations: CT, MRI, height, weight, com-
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plete blood count, hemoglobin level, kidney/liver
function, electrolyte levels, and calcium and magnesium concentrations, and a caloric intake per day by
oral route (<1500 kcal were excluded).
Regarding postoperative adjuvant chemotherapy, patients eligible for the analysis should have a
complete and detailed medical record and a report
with gastroscopy, pathological, CT or MRI diagnosis,
quality-of-life assessment, progression-free survival
and overall survival time. And the information was
obtained before chemotherapy and at specific times
during and after drug treatment. Cases that were unclear whether abnormalities on postoperative scans
represented residual tumor or postoperative artifacts,
and cases with combination therapy of chemotherapy,
immunotherapy and/or radiotherapy were all excluded.
Judgments of disease relapse or progression
were based on clinical evidence of gastroscopy,
pathological, CT or MRI diagnosis. Patients who had
clinical evidence of disease progression, despite scans
indicating otherwise, were considered disease progression. The site and date of first relapse, and the
cause and date of death were recorded. The sites of
relapse were classified as follows: the relapse was
coded as: loco-regional if tumor was detected within
the operation fields (including gastric bed, remnant
stomach, and surgical anastomosis); peritoneal if tumor was detected in the peritoneal cavity; and distant
if the metastases were diagnosed outside the peritoneal cavity or liver metastasis.

Real time qRT-PCR analysis
First-strand cDNA was synthesized using the
Bio-Rad RT kit. Primer sequences are available upon
request. Real-time qRT-PCR assays were carried out
on a Bio-Rad iCycler iQ system (Bio-Rad, Hercules,
CA, USA) using SYBR Green reagent as described
[19].

Construction of eukaryotic expression vector
containing wild type and T889C mutants of
POLB gene and transient transfection
The entire coding region of POLB cDNA containing wild type or T889C mutant, and site-directed
mutagenesis were amplified by RT-PCR, and cloned
respectively in a pcDNA3.1 vector before transfecting
into AGS cells. 5 X105 cells were plated in 10 cm2 culture dishes, 25 pg of plasmid DNA/dish were transfected using the calcium phosphate precipitation
method.

Immunofluorescence assays
Cells were seeded at 2 × 104 cells per well on
glass coverslips in six-well plates and fixed in 2%
http://www.ijbs.com
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paraformaldehyde as described previously [19].
Confocal images were obtained using a LSM 510
Confocal microscope (Carl Zeiss). The number of nuclei containing at least one localized area of immunofluorescence was determined by examination of the
confocal images. Antibodies for immunofluorescence
were as follows: goat polyclonal antibody POLB
(sc-5927, Santa Cruz) at final concentration of 1:800,
Alexa Flour 568 goat anti-mouse IgG (Invitrogen),
1:500 and Alexa Flour 568 goat anti-mouse IgG (Invitrogen), 1:500.

suspended in 100 μl of serum-free medium before
adding to the upper chamber of the Transwell insert.
The lower chamber was filled with 500 μl of the medium with 0.1% bovine serum albumin. After 24 h of
incubation at 37°C, the cells on the upper surface of
the filter were removed using a cotton swab. The cells
that penetrated to the lower surface of the filter were
stained with hematoxylin and counted under an
Olympus IX70 microscope (Olympus) in 13 randomized fields at ×400 magnification. The assay was performed four times as described earlier [20, 21].

POLB knockdown assays

Plasmid treatment with UV/anticancer drugs
and host cell reactivation (HCR) assays

The siRNA targeting POLB was purchased from
Qiagen (SI02663605: 5′-TACGAGTTCATCCATCA
ATTT-3′). siRNAs against GAPDH (SI02653266 and
SI03650325, Qiagen) were used as positive and negative controls, respectively. Cells were transfected with
40 pmol of siRNA using the HiPerFect lipid transfection reagent (Qiagen), and harvested at 24h, 48h and
72 h post-transfection. POLB expression was then analyzed at both mRNA and protein level by qRT–PCR
and Western blotting, respectively.

Chemosensitivity and MTT assays
To determine the sensitivity of GC cell lines to
chemotherapy, BGC823, SGC7901, AGS and N87 cells
were seeded in a 96-well plate as described [20]. 5-FU,
cisplatin and epirubicin were obtained from the
pharmacy at Beijing Cancer Hospital (Beijing, China).
Test drug concentrations were 5 to 400 µg/mL for
5-FU, 0.5 to 8 µg/mL for cisplatin and 0.025 to 1.6
µg/mL for epirubicin. The cells were treated by either
single or a variety of combinations for analysis. Cells
were seeded in a 96-well plate at the density of 3× 104
per well, and were incubated in medium containing
5% serum. The attached cells in the plates were
washed once with PBS, and then replaced with fresh
medium containing various concentrations of drugs
to treat for 24h and 48 h. To further confirm the effect
of the T889C on chemotherapy, the wild type, T889C
mutant or empty vector transfected AGS cells were
subject to MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) assays at 24h, 48h and
72h. At each time point, 10 µl of MTT reagent
(MILLIPORE, Billerica, MA, USA) was added to each
well. After 4 h of incubation, cells were lysed by addition of 200 μl DMSO. Absorbance was measured at
570 nm wavelength. Experiments were repeated three
times, and the percentage of growth was the average
of the experiments.

DNA repair capability of cells with wild-type
and T889C mutant POLB were assessed using
post-UV HCR as described previously [19] [20].
pCMVLuc reporter gene plasmid (a kind gift from Dr.
Kenneth H. Kraemer, National Cancer Institute ) was
dissolved in 10 mm Tris-HCl, 1 mm EDTA, pH 8 (TE
buffer) to a final concentration of 100 μg/ml and
poured in a Petri dish to form 1D 2 mm thick layer.
The Petri dish was placed on ice and irradiated by
1000 J/m2 of UV light. For the drug treatment, 1 μl
aliquots of a stock solution of 1 μg / μl cisplatin, 10 μg
/ μl 5-FU and 0.01 μg / μl cisplatin (Sigma-Aldrich, St.
Louis, MO) in TE were added to 10 μg plasmid DNA
before dissolving in 200 μl TE buffer, and then the
samples were incubated at 37°C for 6 h. At the end of
the incubation, 1 M NaCl was added to a final concentration of 0.2 M NaCl. The plasmid DNA was precipitated with 2 volumes of 100% ethanol, and then
washed with 70% ethanol. The pellets were air-dried
and dissolved in TE buffer. DNA repair capability of
cells was assessed using HCR with the CsCl-purified
pCMVLuc plasmid treated by UV or drugs. Four microliters (200 ng) of damaged or undamaged
pCMVLuc were co-transfected with 0.4 µl (200 ng) of
wild-type, and T889C mutant POLB effector plasmids
into cells using Lipofectamine 2000 (Invitrogen). To
estimate the DNA repair capacity after POLB knockdown, we co-transfected pCMVLuc with 40 pmol of
siRNA, relative luciferase activities were determined
by a percentage of activities obtained with treated
versus untreated control plasmids.

Statistical analysis
Means ± SD were calculated, and statistical
analysis was performed using one-way ANOVA, followed by the nonparametric Kruskal-Wallis test; p <
0.05 was considered statistically significant.

Transwell matrigel invasion assays

Protein-structure modelling

The cell line AGS transfected with wild-type and
mutant POLB was harvested using a cell-dissociation
solution at 90% confluence. The cells (1 × 105) were

A three-dimensional model of the L259S mutation was created by comparative protein modelling
methods [22]. The crystal structure of human POLB
http://www.ijbs.com
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(PDBid: 4JWM) at 2.0-Å resolution [23] was used as a
template as justified by a 98.5% identity in amino-acid
sequence alignment. Using the model-building program O [24, 25], residue E256 was replaced with aspartate to restore the active site back to that of the
wild type, and residue L259 was replaced with serine
to model the natural occurring mutation in cancer
patients. The peptide backbones were not adjusted.
Side chains were adjusted based on likelihood of
nearby hydrogen-bonds partners within a distance of
~3.5 Å. Protein residue numbering corresponds to the
coding sequence within genbank accession M13140.1.
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Results
T889C point mutation screening in a new cohort of GC patients
In order to investigate the incidence of T889C
mutation in GC, we established a new cohort of 177
GC patients (Table 1). To facilitate large-scale T889C
point mutation screening, a strategy based on
PCR-RFLP was designed to characterize the mutation
(Figure 1A). The feasibility of this strategy was firstly
tested in 13 GC cell lines. PCR products from cell lines
with T889C mutant POLB, BGC823, MGC803,
SGC7901 and PAMC82 [15] were able to be cut by
Taq1, but not for those with wild type POLB, AGS,
N87 and MKN45. Thus, the PCR-RFLP indeed provided a reliable and simple approach for detecting the
T889C mutation (Figure 1B).

Figure 1. Identification of the T889C mutation in primary GCs with PCR-RFLP, DHPLC and DNA sequencing. A. Restriction analysis of the POLB gene fragment
amplified by PCR. RFLP patterns obtained after digestion of PCR products with Taq1 endonucleases. Primers were designed to amplify the region spanning 3’ region of intron 12
to 5’ region of exon 13 in POLB gene and length of the PCR products were 260bp. T889C mutation formed of a new Taq1 site from nucleotide 888 to 891 (TTGA to TCGA) of
POLB (NM_002690.1) cDNA and therefore, the amplified product could be digested with Taq1. The molecular weights of digested fragments were 149bp and 111bp. B. The
digested fragments were separated by 2.0% agarose gel electrophoresis. 100-bp ladder was used as a size marker. PCR products (260bp) amplified from BGC823, MGC803,
SGC7901 and PAMC82 cell lines (carrying the T889C mutation) could be digested by Taq1, the molecular weights of digested fragments were 149 and 111bp while those from
AGS, N87 and MKN45 cell lines couldn’t be digested by Taq1. C. Restriction patterns obtained by Taq1 digestion of amplified product from GC tissues. The digested fragments
were separated by 2.0% agarose gel electrophoresis and 100bp ladder was used as a size marker. PCR products (260bp) with T889C mutation could be digested by Taq1, the
molecular weights of digested fragments were 149 and 111bp while the PCR products with wild type POLB couldn’t be digested by Taq1. D. Chromatograph of DHPLC and
sequencing analysis.

http://www.ijbs.com
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We examined 177 primary GCs. The T889C point
mutation was detected in 18 (10.17%) of them (Figure
1C), but not in any of the matched normal gastric tissues or the 50 normal volunteer controls (Figure 1D).
These data indicate that T889C mutation may represent an important genetic risk factor for human GCs.
Since point mutations could alter gene function
by either reducing (loss-of-function mutations) or
increasing (gain-of-function mutations) its expression
level, we examined the relationship between T889C
mutation and expression of POLB in GC tissues. We
constructed tissue microarrays consisting of samples
from 70 GC patients, including 18 with- and 52 without- T889C mutation, and 20 normal adjacent tissues
(5 from patients with- and 15 without- T889C mutation). The positive hybridization signals of POLB
protein were observed in 47 (67.1%) of the 70 GCs, of
which, 16 (88.9%) of 18 with T889C mutation, and 31
(59.6 %) of 52 without. There was a significant positive
association between T889C point mutation and positive signals of POLB protein (p = 0.023, Figure 2A-F
and Supplementary Material: Table S1). The concordance between T889C mutation and overexpression of POLB was confirmed by RT-PCR and Western
blot analysis, respectively (Figure 2G & 4C).
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Association of clinicopathological features
with T889C mutation and POLB overexpression
We analyzed the relationship between T889C
mutation and gender, age, tumour location, depth of
invasion, differentiation and metastasis in 177 primary GCs. Lymph node metastases was found in all
18 GC patients carrying T889C mutation (100%),
whereas in 99 of the rest of the 159 patients (62.26%) .
There were significant differences between the patients with- and without- T889C mutation in regard to
the propensity of lymph nodes metastasis (p = 0.002,
Supplementary Material: Table S2). GC harboring
T889C mutation was more likely to metastasize to
lymph nodes. Furthermore, mutation occurred in 14
(14.58%) of 96 poorly differentiated primary GCs and
4 (4.94%) of 81 moderately/well differentiated tumors
(p = 0.034, Supplementary Material: Table S2). Thus
the T889C mutation is more prevalent in poorly differentiated primary GCs compared with those of
moderately/well differentiated tumors. However, we
did not find any significant correlation between
T889C mutation and gender, age, tumour location or
depth of invasion (p > 0.05). These findings suggest
that T889C mutation is strongly associated with metastasis and differentiation in human GC.
We next analyzed the relationship between
POLB expression and clinicopathological features. By
analyzing the 70 samples on our tissue array, we
found that POLB positivity was not associated with
lymph nodes metastasis, poorly differentiation, age,
gender, tumour location and depth of invasion (p >
0.05), despite that T889C mutation was significantly
associated with poor differentiation (p = 0.009) and
lymph nodes metastasis (p = 0.018). Our data suggested that POLB expression alone is not associated
with clinicopathological features.

T889C mutation is associated with the response to postoperative chemotherapy

Figure 2. POLB expression on tissue array by immunohistochemistry,
RT-PCR and Western blot analysis in GC patients. A, B and C. With T889C
mutation; D and E. Without T889C mutation; F. Normal tissue. G. RT-PCR (top) and
Western blot (bottom) analysis of POLB gene in GC tissues with-T889C mutation
(lanes 1-3) and without- (lanes 5-6).

POLB plays a significant role in chemotherapeutic agent resistance [26]. Among the 177 cases, 143
patients received postoperative adjuvant chemotherapy. Nineteen GC patients were analyzed to reveal
the relationship between the mutation and the response to postoperative chemotherapy as they were
diagnosed at the same clinicopathological stage) before surgery, and treated with the same anticancer
drugs/doses. They were all at stage T4N2M0, and
treated with cisplatin (60 mg / m2 i.v.) and epirubicin
(50 mg / m2 i.v.), every 3 weeks for four cycles together with a continuous 12 week infusion of 5-FU
(200 mg / m2 /day). The estimated median progression-free and overall survival times were 11±1.405 and
16±4.265 months, respectively. Significant differences
http://www.ijbs.com
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in progression-free and survival time were found
between patients with T889C mutation (8) and those
without the mutation (11) (p=0.026), and significant
difference also existed in overall survival (16±4.265 vs.
24±8.34, p=0.027) between the two groups (Figure
3A&B). Patients with T889C mutation had significantly shorter survival than those without the mutation following chemotherapy. Our data indicates that
T889C mutation is associated with poor response to
postoperative chemotherapy.
To further examine the relationship between alternative POLB and poor response to anticancer
drugs, we assessed the sensitivity of cell lines
BGC823, SGC7901, AGS and N87 to the single-agent
and combinations of 5-FU, cisplatin and epirubicin by
MTT assays. We found that the cell lines with T889C
mutation (BGC823, SGC7901) were more resistant to
5-FU, cisplatin and epirubicin than those with wild
type POLB (Figure 4A&B). These results support the
clinical observation that T889C mutation is associated
with poor response to postoperative chemotherapy.
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Overexpression of POLB gene stimulates proliferation and promotes invasion and migration in human GC cell lines
Having demonstrated the relationship between
T889C mutation, and lymph node metastasis and differentiation in clinical samples, we further examined
the role of T889C mutation in metastasis, differentiation and resistance to anticancer drugs in GC cell
lines. Relative POLB mRNA and protein levels in
transfected AGS cell lines with wild type or T889C
were significantly increased (p<0.01) than that of the
vector control lines, and the receptor genes expressing
both the wild-type and mutant were localized to the
nucleus (Figure 5A). We compared the number of
cells expressing wild type or mutated POLB at 24, 48
and 72 h after transfection. The number of mutant
POLB-transfected cells increased more significantly
than that of the wild-type (Figure 5B). Conversely,
knockdown of POLB by siRNA resulted in a decreased cell growth in AGS cells. Our data suggested
that cells transfected with T889C mutated POLB increased cell proliferation. Next, we examined the invasive and spontaneous metastatic potential by matrigel assays. The invasion of the mutant
POLB-transfected cells was significantly increased
compared with the wild type POLB-transfected cells.
In addition, knockdown of POLB by siRNA reduced
cell growth in AGS cells (Figure 5C). These results
suggest that GC cells with T889C mutation are more
proliferative and invasive.

Expression of POLB with T889C mutation
leads to resistance to chemotherapeutic
agents
In order to further elucidate relationship between T889C mutation and resistance to chemotherapy, we transfected the AGS cell line with either wild
type or T889C mutated POLB, and treated them with
various concentrations of anticancer drugs. We found
that cells transfected with T889C mutant were significantly more resistant to cisplatin and 5-FU compared
to those transfected with empty vectors (Figure 5D).
Inhibition of POLB expression by siRNA restored
chemosensitivity in AGS cells. Our data further corroborates that T889C mutation correlated with poor
response to postoperative chemotherapy.

Overexpression of POLB with T889C mutation
significantly increased post-drugs host cell reactivation activity in GC cell line
Figure 3. Correlation between T889C mutation and survival. Progression-free survival (top) and overall survival (bottom) for all 19 patients enrolled. The
statistical significance of the difference was p = 0.027 and p = 0.026. Patients with
T889C mutation had significantly shorter survival than did patients without the
mutation after postoperative chemotherapy.

POLB participates in regulation of DNA repair
during carcinogen exposure [8]. We then asked
whether overexpression of POLB increases the resistance of the GC cell lines to anticancer drugs via
DNA repair pathway. We measured the luciferase
http://www.ijbs.com
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activity by co-transfecting wild type or T889C mutant
POLB, along with pCMU-Luc vector [19], which was
pre-treated by anticancer drugs respectively, into the
AGS cell line. We found that AGS exhibited significantly increased luciferase activity when the
pCMU-Luc vector was treated with cisplatin and
5-FU. There was no difference in luciferase activity
when the pCMU-Luc vector was treated with epirubicin (Figure 5E). Our data indicate that the T889C
mutation enhances the DNA repair capability in GC
cell line.
When co-transfected AGS with POLB siRNA and
pCMU-Luc vector pre-treated with anticancer drugs,
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DNA repair capability was decreased when
pre-treated with cisplatin and 5-FU. However, there
were no significant DNA repair capability changes
when co-transfected with POLB siRNA and
pCMU-Luc vector pre-treated with epirubicin. These
data demonstrate that the T889C mutation exerts a
distinct effect on DNA repair toward anticancer
drugs, such as cisplatin and 5-FU, but not epirubicin
in GC cell line. Therefore, T889C mutation may be a
gain-of-function mutation affecting chemotherapy
response via DNA repair pathway.

Figure 4. Correlation between T889C mutation and cytotoxicity of 5-fluorouracil, cisplatin and epirubicin. A. Phenotypic comparison of BGC823, SGC7901 and
AGS cell lines before and after treatment. B. Sensitivity of cell lines to cisplatin, epirubicin, 5-fluorouracil and combination treatment with three drugs. Concentration of
5-fluorouracil, cisplatin, epirubicin, and was 5ug/ml, 0.5ug/ml and 0.1ug/ml respectively. The concentration of combination treatment of three drugs is cisplatin 0.5ug/ml, epirubicin
0.1ug/ml, and 5-fluorouracil 5ug/ml. Survival is expressed as the relative plating efficiency of treated cells to the control. The values shown in the figures are mean readings from
six wells in each experiment and representative of at least three independent experiments. C. Protein expression of POLB in cell lines BGC823, SGC7901, AGS and N87.
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A hypothetical model of the human POLB with
T889C mutation
To elucidate the possible mechanism of the
POLB T889C mutation associated functional changes,
we modeled its protein crystallographic structure. The
T889C mutation in the nucleotide sequence of genbank accession M13140.1 would result in an encoded
serine at residue position 259 that would be in hydrogen-bonding proximity to carboxyl groups of residues 232 and 233 on the backbone chain in an adjacent β-strand (Figure 6). These interactions would
distort the β-strand where the serine resides resulting
in a positional shift of the catalytic residue, D256. In
wild type, D256 is stabilized by one of the two bound
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metal ions (Mg2+) and is thought to deprotonate the
O3' group of the primer or newly forming DNA
strand during synthesis [23]. A change in the active
site could either result in a lower activation barrier for
catalysis or simply loosen the constraints in the active
site for the DNA strand to pass with greater flexibility
and speed. There may be additional precedence for a
more efficient active site as other hydrophobic substituted residues, now capable of electrostatic interactions, are also present around the active site, such as
L228R, I260Y, and possibly L287K when comparing
genbank accession number M13140.1
with
AAA60133.1 used in our model (PDBid:4JWM).

Figure 5. The effect of POLB overexpression. AGS cells were transfected with empty pcDNA3.1, wild type POLB, T889C mutant and POLB siRNA. A. Expression of
transfected POLB genes in human GC cell lines. Left panel, representative results of the QRT-PCR analysis of POLB mRNA levels in AGS cell lines. Each reaction was run twice
in triplicates. POLB expression was normalized by GAPDH. Right panel, representative results of the Immunofluorescence for POLB protein expression. POLB protein of both the
wild-type and mutant localized to the nucleus. B. The effect of POLB wild type, mutant and siRNA in AGS cell proliferation. MTT assays indicate cell proliferation rate was
significantly higher in T889C overexpressors (left). The experiments were done three times in triplicates. Right panel shows phenotypic comparison of AGS cell lines before and
after transfection of POLB wild type and mutant and siRNA. C. Matrigel analysis. Three fields of unit area on each membrane were counted for cell numbers, and the experiments
were repeated twice. Data analysis was based on the average of parallel repeats. T889C mutation overexpressing cell lines exhibited very significantly higher invasiveness than
wild type and empty vector control cell lines. D. Resistance assay. The cells were treated with or without 5-fluorouracil, cisplatin, and epirubicin for 24 h. The values are
represented as a mean from three separate experiments; bars, ±SD. E. HCR assay showing increased post-UV DNA repair capability in T889C overexpressors. *p < 0.05.
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Figure 6. A hypothetical model of the human POLB enzyme is shown in complex with DNA, and containing the L259S mutation that is found commonly
in gastric cancer patients. The two known metal ions bound in the active site are shown as magenta spheres. A. The entire enzyme is shown revealing the relative location
of the serine in proximity to the active site. B. A close-up view of additional hydrogen-bond networks is shown in a β-sheet that would lead to a predicted small distortion in the
active site. The figure was made with the program, MOLSCRIPT [38].

Discussion
This study presents a comprehensive picture of
the T889C mutation in POLB gene and its expression
in relation with GC patients’ clinicopathological features. We deciphered the functional relationship between mutant and wild type POLB gene, in association with DNA repair pathway. The T889C mutation
was associated with POLB overexpression, clinicopathological features, such as lymph node metastasis
and differentiation, and response to chemotherapy.
Our clinical and experimental data indicate an oncogenic property in mutant POLB gene in comparison to
the wild type POLB gene in GC. Previous study suggested that POLB exhibits dichotomous functions
depending on its expression, either as an oncogene or
as a tumor suppressor [27-30]. Our data indicate that
T889C mutation in POLB is a relatively frequent
phenomenon and this may be an underlying mechanism for gastric cell mutagenesis via enhanced DNA
repair pathway. There are two possible reasons where
the L259S substitution may arise naturally. First, it
could allow for higher expression levels. We found a
significant positive association between T889C mutation and overexpression of POLB gene. However, the
exact mechanism by which T889C mutation leads to
POLB gene overexpression is not clear. We hypothesize that epigenetic factors may be involved, which
would be our direction for future investigation. Second, beyond epigenetics, a serine substitution could
conceivably increase the specific activity of the polymerase in crisis. Detailed X-ray crystallographic
studies are needed to determine the effects of the
substitutions in the active site.

DNA repair and the fidelity of DNA relegation
have been found to be correlated with metastatic potential [31-33]. We discovered that T889C mutation,
but not POLB overexpression alone, was significantly
correlated to increased lymph nodes metastasis. Our
data suggests that abnormally enhanced DNA repair
capability increases the risk of tumor metastasis for
GC.
Previous studies suggested that POLB may play
a fundamental role in cellular differentiation [34, 35].
Our results further demonstrated that poorly-differentiated tumors carried higher frequency of
T889C mutation than moderately/well differentiated
tumors. We hypothesize that the poor differentiation
associated with T889C mutation may be due to the
disruption of DNA repair synthesis or DNA translation synthesis during differentiation, or by facilitating
accumulation of mutations in differentiation-related
genes.
POLB has been found to efficiently bypass the
cisplatin adduct [36]. Studies showed that abnormal
POLB expression associated with the cytotoxic effects
of DNA damaging chemotherapeutic agents [37]. In
this study, we showed that T889C mutation of POLB
gene was correlated closely with a poor response to
5-FU, cisplatin and epirubicin in GC patients. It is
suggested that T8889C mutation might facilitate cell
survival by enhancing DNA repair capability, to bypass various DNA damages by commonly used
chemotherapeutic drugs.

Conclusions
The T889C mutation in POLB gene is a prevalent
event among GC patients. The alteration of POLB
http://www.ijbs.com
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gene mutation and expression is associated with the
pathological features including differentiation, lymph
nodes metastasis, and poor prognosis via DNA repair
pathway. Thus, the POLB gene with T889C mutation
in surgically resected primary gastric tissues may be
clinically useful for predicting responsiveness to
chemotherapy in patients with GC. The POLB gene
alteration may serve as a prognostic biomarker for
GC.
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